Korea Continuous Glucose Monitoring Devices Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Korea Continuous Glucose Monitoring Devices Market Trends and Insights

Reimbursement Expansion Under Korea's National Health Insurance (NHIS)

Policy support serves as an immediate catalyst, reducing out-of-pocket costs for priority groups and encouraging continuous sensor use. Coverage improvements have coincided with a marked age gradient in uptake, with national cohort data showing higher continuous use among younger individuals and lower use among older adults who face more barriers to adoption. Clinical societies have updated guidance in favor of real-time CGM for all adults with Type 1 diabetes and for those with Type 2 diabetes who require intensified insulin therapy, which aligns clinical practice with payer objectives to prevent severe hypoglycemia and improve time in range^{[1]Source: Korean Diabetes Association, “2025 Clinical Practice Guidelines for Diabetes Management in Korea,” Diabetes & Metabolism Journal, pmc.ncbi.nlm.nih.gov}. Economic evaluations conducted in South Korea find that real-time CGM is cost-effective in insulin-intensive Type 2 diabetes, which informs coverage evaluations and underscores the budget impact of fewer acute complications. The reimbursement review process also emphasizes device quality and safety, which means vendors need to provide robust clinical evidence and comply with local submission standards to sustain funding. Over time, streamlined implementation and education will remain essential so that policy improvements translate into continuous real-world usage among eligible patients.

Rapid Uptake Of CGM-Enabled Artificial‐Pancreas Research Programs

Automated insulin delivery systems are bringing CGM into more care pathways by linking sensors, pumps, and algorithms into closed-loop operation. Standards of care for 2026 recommend AID for adults with Type 1 diabetes and recognize the role of CGM within comprehensive insulin management, which supports clinical and payer alignment around these platforms. Korean guidelines also elevate real-time CGM in Type 1 diabetes and define best practices for integrating sensor data into dose titration, which underpins training protocols in tertiary hospitals. Domestic R&D programs continue to explore device integration and data-driven dose guidance, which may widen AID benefits beyond pump users to multiple daily injection cohorts. As algorithms mature, hospital adoption and home use reinforce each other because the same sensor platforms support both inpatient and outpatient workflows.

Growing Demand From Type-2 Diabetics On GLP-1 Therapy

Behavioral and pharmacologic synergies are shifting attention to non-insulin Type 2 diabetes care pathways. Clinical guidance emphasizes that CGM feedback helps adjust meal timing and activity patterns, which complements the appetite and gastric-emptying effects of GLP-1 receptor agonists for glycemic control. Korean guidelines recognize real-time CGM in patient groups that benefit from continuous data, and this creates a foundation for combination approaches where therapy adjustments require near-real-time feedback. The broader clinical community also highlights how CGM can support medication optimization through improved time in range and fewer hypoglycemia events, which is particularly relevant when intensifying or de-intensifying therapy. As digital tools evolve, data sharing between patients and care teams enables targeted interventions that fit into routine care, rather than frequent clinic visits. Together, these changes expand the addressable user base for the South Korea Continuous Glucose Monitoring market in early-stage Type 2 management, where lifestyle feedback can shape outcomes.

Next-Gen Multi-Analyte (Glucose + Ketone) Sensors Entering KMFDS Trials

Platform innovation aims to deliver more analytes, longer wear, and simpler workflows. Clinical reviews describe progress toward achieving reduced calibration, sub-10% MARD accuracy, and app-based analytics that make sensor data more actionable for clinicians and users. The addition of ketone monitoring has clear relevance for patients at risk of euglycemic diabetic ketoacidosis in certain therapy combinations, and clinical guidance continues to emphasize risk mitigation for these regimens. Improvements in sensor chemistry and signal processing enable longer wear windows, which can increase adherence and reduce replacement burden without compromising accuracy. As vendors validate multi-analyte designs under local submission standards, clinical utility will center on the earlier detection of acute risk and the provision of finer-grained guidance for therapy adjustments. These features broaden the role of CGM and support further adoption in the South Korea continuous glucose monitoring market, as clinical teams target both long-term outcomes and near-term safety.

Monopolized Import Channel & High Device ASPs

Device affordability remains a barrier for users who do not qualify for higher reimbursement or who face budget constraints. Domestic manufacturing capacity is expanding, which can lower landed costs and shorten supply lines for sensors and receivers. Cost-utility research in South Korea supports funding for intensive insulin users, yet patients outside prioritized groups still weigh ongoing sensor costs against limited budgets. Uptake patterns confirm that continuous use is higher among younger and more digitally engaged cohorts, and lower among older adults who are more sensitive to recurring expenses and required device training. As local vendors improve scale and as reimbursements evolve, price dispersion can narrow and help the South Korea continuous glucose monitoring market reach new patient segments. In the meantime, clinicians and payers continue to target groups that derive the greatest clinical and economic benefits from continuous use.

Physician Scepticism Over Non-Adjunctive Use In Primary Care

Training, liability, and workflow gaps can reduce prescription rates outside tertiary centers. National cohort data show that only a minority of eligible adults with Type 1 diabetes used CGM continuously, and utilization was highest among pediatric users who benefit from caregiver support and structured education. Clinical guidance endorses real-time CGM for Type 1 diabetes and for insulin-intensive Type 2 diabetes, yet adoption in community clinics can lag due to limited time for data interpretation and fewer resources for structured onboarding. As standard operating procedures for ambulatory glucose profile interpretation and dose titration expand, familiarity rises, and inertia declines. Hospital centers and endocrinology clinics also anchor early use of automated insulin delivery, which then diffuses to broader practice as training models mature. Over the forecast period, structured education and clear clinical governance will be essential to unlock primary care uptake in the South Korea continuous glucose monitoring market.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Component: Sensors Anchor Recurring Revenue, Durables Surge on Pump Integration

Sensors account for the largest component share, with 76.78% in 2025, driven by recurring replacement cycles and widespread clinical endorsement for real-time monitoring. Advances in accuracy and reduced calibration have raised patient confidence, while app-based analytics improve visibility into trends that inform therapy adjustments. Clinical guidance has clarified how to use time-in-range metrics to guide treatment, which further legitimizes the role of sensors in standardized care pathways. Domestic vendors have launched calibration-free platforms with competitive MARD and faster warm-up, which strengthen local value propositions and support broader uptake across age groups. As these features consolidate into baseline expectations, competition moves toward wear comfort, seamless data sharing, and compatibility with clinical dashboards that fit into hospital and clinic workflows.

Durable components, including receivers and transmitters, are expanding at the fastest clip with a 16.86% CAGR. User preferences vary by age and setting because some cohorts favor smartphone-native monitoring while others need dedicated displays for simplicity and accessibility. Closed-loop systems validate the role of reliable communication hardware that can sustain high-frequency data exchange for algorithmic control, which helps define performance benchmarks for the category. Domestic offerings of receivers and app updates also reflect attention to localization, language, and user-interface design, which encourages adoption in older adults who need straightforward displays. As platforms converge on accuracy, the South Korea continuous glucose monitoring industry is differentiating on ecosystem depth, app usability, and the quality of integration with hospital systems.

By End User: Homecare Primacy Masks Hospital Surge Driven by Inpatient Hypoglycemia Protocols

Home or personal settings represent 75.97% of end-user share in 2025 as patients prioritize convenience, real-time alerts, and fewer clinic visits for routine glucose management. Telemedicine pilots and remote monitoring workflows allow clinicians to review CGM data asynchronously, which reduces friction for therapy adjustments between in-person visits. Clinical guidelines support the use of real-time sensor data to drive time-in-range improvements, which strengthens physician confidence in virtual follow-up for eligible patients. As a result, the South Korean continuous glucose monitoring market has a strong home care foundation that reflects both user preference and evolving clinical workflows.

Hospitals and clinics are growing faster at 15.63% CAGR as inpatient protocols adopt CGM for insulin titration, perioperative control, and high-risk monitoring. Closed-loop systems validated in specialty centers help create templates for broader rollouts across tertiary networks, which then standardize training and interpretation. As data flows into care teams earlier in the patient journey, hospitals can use the same sensor platforms for both inpatient and discharge planning, which increases continuity and adherence at home. These patterns reinforce South Korea's continuous glucose monitoring industry’s shift toward integrated care that spans settings instead of siloed device use.

By Demography: Adult Dominance Masks Pediatric Surge Fueled by Coverage and Adherence

Adults represent 60.95% share in 2025, reflecting the burden of Type 2 diabetes in older cohorts and their need for structured glycemic control strategies. National cohort evidence shows that continuous use has been higher in younger groups and lower in older adults, which signals the importance of education, simplified apps, and caregiver features in raising adherence among seniors. Clinical guidance details how to translate sensor data into dose changes for insulin-intensive patients and when to rely on alarm features to avoid severe hypoglycemia, which supports adult-focused therapy intensification. Over time, adult adoption should benefit from easier onboarding and broader coverage for groups with the greatest gains in time in range and complication risk reduction^{[2]Source: Ministry of Health and Welfare, “Pilot Program for Tele-medical Service Kicks Off,” Ministry of Health and Welfare, mohw.go.kr}.

Pediatrics is the fastest-growing demographic with a 15.49% CAGR because caregiver support, high alert utility, and improved access encourage continuous use. National data show that pediatric users adopt CGM more consistently than older adults, and predictive alerts are especially valued in school and nighttime settings. Korean guidance supports universal real-time CGM for Type 1 diabetes in children, which directs training and resource allocation toward effective long-term control in youth. As capabilities migrate into everyday devices and caregiver apps, the South Korea continuous glucose monitoring market will capture sustained pediatric growth supported by strong clinical consensus.

Geography Analysis

Regional adoption varies with provider density, digital readiness, and logistics. Uptake concentrates around tertiary centers where endocrinology teams and device training programs are established, and this concentration raises visibility for continuous use among local clinics that share care pathways with those centers. Younger cohorts that are more comfortable with apps and wearables also cluster in metropolitan areas, which supports a higher baseline of continuous use relative to rural settings. These dynamics help the market build a larger installed base in urban areas that can diffuse out as training and access expand.

Telemonitoring pilots reduce geographic barriers by allowing data review without travel. Government pilots and legal clarifications support remote interpretation of physiological data, which is central to CGM-led diabetes management plans outside major cities^{[3]Source: Ji Yoon Kim et al., “Real-time continuous glucose monitoring vs. self-monitoring of blood glucose: cost-utility in South Korean type 2 diabetes patients on intensive insulin,” Journal of Medical Economics, tandfonline.com}. As those programs mature, standard protocols for consent, security, and clinical action can help smaller clinics integrate CGM into routine follow-up, which lifts adoption in underserved regions. Over the medium term, continued investment in digital literacy and education should reinforce steady expansion of the market beyond metropolitan hubs.

Referral patterns also shape regional access. Hospitals that deploy closed-loop systems become centers for training and device onboarding, which then influence how nearby clinics prescribe and monitor CGM. As these networks share protocols and data templates, clinicians across regions can apply uniform standards in dose adjustment and hypoglycemia prevention. In parallel, domestic vendors provide localized support, language-specific interfaces, and supply capacity that reduce friction for clinics and pharmacies outside major cities, thereby contributing to increased market access.

Regulatory Landscape

South Korea regulates continuous glucose monitoring (CGM) devices under the Ministry of Food and Drug Safety (MFDS) medical device framework, with added obligations for connected software and cloud-enabled functions that accompany real-time CGM and automated insulin delivery (AID) ecosystems. A major structural change came with the Digital Medical Products Act (DMPA), which took effect on January 24, 2025, establishing a dedicated framework for digital health products and clarifying expectations around digital medical devices that rely on software, connectivity, and data processing in routine use.

In early 2026, MFDS Notice 2026-6 revised the Regulation on Medical Device Approval, Notification, and Review, tightening submission and review expectations relevant to sensor performance, software behavior, and lifecycle documentation. Manufacturing oversight also moved further toward lifecycle control, with updated Medical Device GMP regulations released in February 2026 that more closely integrate manufacturing controls with post-market surveillance expectations. For manufacturers operating in Korea or supplying Korea, the combined KGMP and MDSAP audit option introduced on April 7, 2025 reduces duplicative audit burden, while reimbursement is shaped by National Health Insurance Service (NHIS) coverage that provides partial support for CGM sensors and transmitters for Type 1 diabetes patients.

Market Opportunities and Future Outlook

A key whitespace in South Korea CGM sits in import substitution and broader price access: domestic CGM share has been cited at 7.5% versus 92.5% reliance on imports (including Abbott FreeStyle Libre 2, Dexcom G7, and Medtronic Guardian 4). This imbalance creates room for domestic scaling in sensors and supporting durables that can compete on landed cost and local service, particularly as vendors align with MFDS requirements for digital-device lifecycle documentation and with NHIS reimbursement processes. i-SENS has positioned CareSens Air as a lower-cost alternative and has continued its international rollout (including markets such as Germany, the Netherlands, the UK, and Poland), reinforcing a pathway where manufacturing scale and regulatory-ready evidence packages translate into stronger tender and reimbursement positioning.

Digital integration is another active opportunity area, as Korea-specific platforms increasingly connect CGM data into clinical visualization and remote monitoring workflows. Abbott Korea has linked FreeStyle Libre 2 data with the LabConnect platform by iKooB (a GC Biopharma affiliate), and Dexcom has moved beyond device supply toward platform linkage through an exclusive domestic supply contract with Kakao Healthcare to connect sensor technology with the PASTA AI-based blood glucose management platform. With the market reported to have grown nine-fold between 2020 and 2024 and reaching around KRW 127 billion in 2025, initiatives that expand real-world utility (alerts, sharing, clinician dashboards, and AID-ready interoperability) provide practical routes to deepen use beyond early adopter populations while supporting hospitals, clinics, and telemonitoring pathways.